Regulation of apoptosis by the papillomavirus E6 oncogene

World Journal of Gastroenterology

Volumn 11, Issue 7, 2005, Pages 931-937

  Li, Ting Ting ^a   Zhao, Li Na ^a   Liu, Zhi Guo ^a   Han, Ying ^a   Fan, Dai Ming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; E6; Esophageal squamous cell carcinoma; HPV

Indexed keywords

DOUBLE STRANDED DNA; GLYCOPROTEIN E; ONCOPROTEIN; PROTEIN P21; PROTEIN P53;

APOPTOSIS; CARCINOGENICITY; CELL GROWTH; CELLULAR DISTRIBUTION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE INACTIVATION; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR MECHANICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SENSITIZATION; SIGNAL TRANSDUCTION; VIRUS INFECTION; WART VIRUS;

EID: 14844300812     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i7.931     Document Type: Review

References (107)

1. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286: 3106-3114
2. Pfister H. Human papillomaviruses and skin cancer. Semin Cancer Biol 1992; 3: 263-271
3. Syrjanen KJ. Histological changes identical to those of condylomatous lesions found in esophageal squamous cell carcinomas. Arch Geschwulstforsch 1982; 52: 283-292
4. Winkler B, Capo V, Reumann W, Ma A, La Porta R, Reilly S, Green PM, Richart RM, Crum CP. Human papillomavirus infection of the esophagus. A clinicopathologic study with demonstration of papillomavirus antigen by the immunoperoxidase technique. Cancer 1985; 55: 149-155
5. Awerkiew S, Bollschweiler E, Metzger R, Schneider PM, Holscher AH, Pfister H. Esophageal cancer in Germany is associated with Epstein-Barr-virus but not with papillomaviruses. Med Microbiol Immunol 2003; 192: 137-140
6. Kuwano H, Sumiyoshi K, Sonoda K, Kitamura K, Toh Y, Nakashima H, Sugimachi K. Pathogenesis of esophageal squamous cell carcinoma with lymphoid stroma. Hepatogastroenterology 2001; 48 458-461
7. Talamini G, Capelli P, Zamboni G, Mastromauro M, Pasetto M, Castagnini A, Angelini G, Bassi C, Scarpa A. Alcohol, smoking and papillomavirus infection as risk factors for esophageal squamous-cell papilloma and esophageal squamous-cell carcinoma in Italy. Int J Cancer 2000; 86: 874-878
8. Kamath AM, Wu TT, Heitmiller R, Daniel R, Shah KV. Investigation of the association of esophageal carcinoma with human papillomaviruses. Dis Esophagus 2000; 13: 122-124
9. Lambot MA, Haot J, Peny MO, Fayt I, Noel JC. Evaluation of the role of human papillomavirus in oesophageal squamous cell carcinoma in Belgium. Acta Gastroenterol Belg 2000; 63: 154-156
10. Peixoto Guimaraes D, Hsin Lu S, Snijders P, Wilmotte R, Herrero R, Lenoir G, Montesano R, Meijer CJ, Walboomers J, Hainaut P. Absence of association between HPV DNA, TP53 codon 72 polymorphism, and risk of oesophageal cancer in a high-risk area of China. Cancer Lett 2001; 162: 231-235
11. Kawaguchi H, Ohno S, Araki K, Miyazaki M, Saeki H, Watanabe M, Tanaka S, Sugimachi K. p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res 2000; 60 2753-2755
12. Chang F, Syrjanen S, Shen Q, Cintorino M, Santopietro R, Tosi P, Syrjanen K. Evaluation of HPV, CMV, HSV and EBV in esophageal squamous cell carcinomas from a high-incidence area of China. Anticancer Res 2000; 20: 3935-3940
13. Chang F, Syrjanen S, Shen Q, Cintorino M, Santopietro R, Tosi P, Syrjanen K. Human papillomavirus involvement in esophageal carcinogenesis in the high-incidence area of China. A study of 700 cases by screening and type-specific in situ hybridization. Scand J Gastroenterol 2000; 35: 123-130
14. Liu YL, Li XM, Jin GL, Yan X, Yang JZ, Wang JL, Li YH, Wang FR, Zhang XH. HPV detection and FHIT expression in esophageal squamous carcinoma from high incidence area in Cixian County. Aizheng 2003; 22: 492-495
15. Szentirmay Z, Szanto I, Balint I, Polus K, Remenar E, Tamas L, Szentkuti G, Melegh Z, Nagy P, Kasler M. Causal association between human papilloma virus infection and head and neck and esophageal squamous cell carcinoma. Magy Onkol 2002; 46: 35-41
16. Hasegawa M, Ohoka I, Yamazaki K, Hanami K, Sugano I, Nagao T, Asoh A, Wada N, Nagao K, Ishida Y. Expression of p21/WAF-1, status of apoptosis and p53 mutation in esophageal squamous cell carcinoma with HPV infection. Pathol Int 2002; 52: 442-450
17. Matsha T, Erasmus R, Kafuko AB, Mugwanya D, Stepien A, Parker MI. Human papillomavirus associated with oesophageal cancer. J Clin Pathol 2002; 55: 587-590
18. Astori G, Merluzzi S, Arzese A, Brosolo P, de Pretis G, Maieron R, Pipan C, Botta GA. Detection of human papillomavirus DNA and p53 gene mutations in esophageal cancer samples and adjacent normal mucosa. Digestion 2001; 64: 9-14
19. Lu Z, Chen K, Guo M. Detection of HPV in human esophageal cancer in high-incidence area and its correlation with p53 expression. Zhonghua Zhongliu Zazhi 2001; 23: 220-223
20. Zhou XB, Guo M, Quan LP, Zhang W, Lu ZM, Wang QH, Ke Y, Xu NZ. Detection of human papillomavirus in Chinese esophageal squamous cell carcinoma and its adjacent normal epithelium. World J Gastroenterol 2003; 9: 1170-1173
21. Shen ZY, Hu SP, Lu LC, Tang CZ, Kuang ZS, Zhong SP, Zeng Y. Detection of human papillomavirus in esophageal carcinoma. J Med Virol 2002; 68: 412-416
22. Xu WG, Zhang LJ, Lu ZM, Li JY, Ke Y, Xu GW. Detection of human papillomavirus type 16 E6 mRNA in carcinomas of upper digestive tract. Zhonghua Yixue Zazhi 2003; 83: 1910-1914
23. Sobti RC, Kochar J, Singh K, Bhasin D, Capalash N. Telomerase activation and incidence of HPV in human gastrointestinal tumors in North Indian population. Mol Cell Biochem 2001; 217: 51-56
24. Xu CL, Qian XL, Zhou XS, Zhao QZ, Li YC. Expression of HPV16-E6 and E7 oncoproteins in squamous cell carcinoma tissues of esophageal cancer and non-cancer tissues. Aizheng 2004; 23: 165-168
25. Acevedo-Nuno E, Gonzalez-Ojeda A, Vazquez-Camacho G, Balderas-Pena Luz MA, Moreno-Villa H, Montoya-Fuentes H. Human papillomavirus DNA and protein in tissue samples of oesophageal cancer, Barrett's oesophagus and oesophagitis. Anticancer Res 2004; 24 1319-1323
26. Li T, Lu ZM, Chen KN, Guo M, Xing HP, Mei Q, Yang HH, Lechner JF, Ke Y. Human papillomavirus type 16 is an important infectious factor in the high incidence of esophageal cancer in Anyang area of China. Carcinogenesis 2001; 22: 929-934
27. Syrjanen KJ. HPV infections and oesophageal cancer. J Clin Pathol 2002; 55: 721-728
28. Togawa K, Rustgi AK. Human papillomavirus-16 and -18 replication in esophagus squamous cancer cell lines does not require heterologous E1 and E2 proteins. J Med Virol 1995; 45: 435-438
29. Jarrett WF, McNeil PE, Grimshaw WT, Selman IE, McIntyre WI. High incidence area of cattle cancer with a possible interaction between an environmental carcinogen and a papilloma virus. Nature 1978; 274: 215-217
30. Shen Z, Cen S, Shen J, Cai W, Xu J, Teng Z, Hu Z, Zeng Y. Study of immortalization and malignant transformation of human embryonic esophageal epithelial cells induced by HPV18 E6E7. J Cancer Res Clin Oncol 2000; 126: 589-594
31. Shen ZY, Xu LY, Li EM, Cai WJ, Shen J, Chen MH, Cen S, Tsao SW, Zeng Y. The multistage process of carcinogenesis in human esophageal epithelial cells induced by human papillomavirus. Oncol Rep 2004; 11: 647-654
32. Omata M, Mori J, Yokosuka O, Iwama S, Ito Y, Okuda K. Hepatitis B virus antigens in liver tissue in hepatocellular carcinoma and advanced chronic liver disease-relationship to liver cell dysplasia. Liver 1982; 2: 125-132
33. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985; 314: 111-114
34. Alvarez-Salas LM, Cullinan AE, Siwkowski A, Hampel A, DiPaolo JA. Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes. Proc Natl Acad Sci USA 1998; 95:1189-1194
35. Barbosa MS, Lowy DR, Schiller JT. Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol 1989; 63: 1404-1407
36. Grossman SR, Laimins LA. E6 protein of human papillomavirus type 18 binds zinc. Oncogene 1989; 4: 1089-1093
37. Kanda T, Watanabe S, Zanma S, Sato H, Furuno A, Yoshiike K. Human papillomavirus type 16 E6 proteins with glycine substitution for cysteine in the metal-binding motif. Virology 1991; 185: 536-543
38. Vousden KH, Androphy EJ, Schiller JT, Lowy DR. Mutational analysis of bovine papillomavirus E6 gene. J Virol 1989; 63: 2340-2342
39. Lamberti C, Morrissey LC, Grossman SR, Androphy EJ. Transcriptional activation by the papillomavirus E6 zinc finger oncoprotein. EMBO J 1990; 9: 1907-1913
40. Foster SA, Demers GW, Etscheid BG, Galloway DA. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 1994; 68: 5698-5705
41. Dalal S, Gao Q, Androphy EJ, Band V. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J Virol 1996; 70: 683-688
42. Ned R, Allen S, Vande Pol S. Transformation by bovine papillomavirus type 1 E6 is independent of transcriptional activation by E6. J Viol 1997; 71: 4866-4870
43. Nguyen ML, Nguyen MM, Lee D, Griep AE, Lambert PF. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol 2003; 77: 6957-6964
44. Watson RA, Thomas M, Banks L, Roberts S. Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J Cell Sci 2003; 116(Pt 24): 4925-4934
45. Kuhne C, Gardiol D, Guarnaccia C, Amenitsch H, Banks L. Differential regulation of human papillomavirus E6 by protein kinase A: Conditional degradation of human discs large protein by oncogenic E6. Oncogene 2000; 19: 5884-5891
46. Androphy EJ, Hubbert NL, Schiller JT, Lowy DR. Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J 1987; 6: 989-992
47. Guccione E, Massimi P, Bernat A, Banks L. Comparative analysis of the intracellular location of the high- and low-risk human papillomavirus oncoproteins. Virology 2002; 293: 20-25
48. Le Roux LG, Moroianu J. Nuclear entry of high-risk human papillomavirus type 16 E6 oncoprotein occurs via several pathways. J Virol 2003; 77: 2330-2337
49. Mallon RG, Wojciechowicz D, Defendi V. DNA-binding activity of papillomavirus proteins. J Virol 1987; 61: 1655-1660
50. Kammer C, Warthorst U, Torrez-Martinez N, Wheeler CM, Pfister H. Sequence analysis of the long control region of human papillomavirus type 16 variants and functional consequences for P97 promoter activity. J Gen Virol 2000; 81(Pt 8): 1975-1981
51. Nomine Y, Charbonnier S, Ristriani T, Stier G, Masson M, Cavusoglu N, Van Dorsselaer A, Weiss E, Kieffer B, Trave G. Domain substructure of HPV E6 oncoprotein: Biophysical characterization of the E6 C-terminal DNA-binding domain. Biochemistry 2003; 42: 4909-4917
52. Ristriani T, Masson M, Nomine Y, Laurent C, Lefevre JF, Weiss E, Trave G. HPV oncoprotein E6 is a structure-dependent DNA-binding protein that recognizes four-way junctions. J Mol Biol 2000; 296 1189-1203
53. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001; 20: 7874-7887
54. Flores ER, Allen-Hoffmann BL, Lee D, Lambert PF. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol 2000; 74: 6622-6631
55. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002; 89 213-228
56. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991; 10: 4129-4135
57. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505
58. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE., Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825
59. Burkhart BA, Alcorta DA, Chiao C, Isaacs JS, Barrett JC. Two posttranscriptional pathways that regulate p21(Cip1/Waf1/Sdi1) are identified by HPV16-E6 interaction and correlate with life span and cellular senescence. Exp Cell Res 1999; 247: 168-175
60. Giannoudis A, Herrington CS. Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses. Cancer 2000; 89: 1300-1307
61. Jackson S, Harwood C, Thomas M, Banks L, Storey A. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000; 14: 3065-3073
62. Filippova M, Song H, Connolly JL, Dermody TS, Duerksen-Hughes PJ. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem 2002;277: 21730-21739
63. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365
64. Wyllie AH, Golstein P. More than one way to go. Proc Natl Acad Sci USA 2001; 98: 11-13
65. Irusta PM, Chen YB, Hardwick JM. Viral modulators of cell death provide new links to old pathways. Curr Opin Cell Biol 2003; 15: 700-705
66. Van Cruchten S, Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002; 31: 214-223
67. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489
68. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME. Two CD95 (APO1/Fas) signaling pathways. EMBO J 1998; 17: 1675-1687
69. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490
70. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501
71. Vousden KH, Lu X. Live or ler die: The cell's response to p53. Nat Rev Cancer 2002; 2: 594-604
72. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80 293-299
73. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-694
74. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477-485
75. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104: 263-269
76. Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW, Greenberg AH. Premature p34cdc2 activation required for apoptosis. Science 1994; 263: 1143-1145
77. Tan M, Jing T, Lan KH, Neal CL, LI P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 2002; 9: 993-1004
78. Badie C, Itzhaki JE, Sullivan MJ, Carpenter AJ, Porter AC. Repression of CDK1 and other genes with CDE and CHR promoter elements during DNA damage-induced G(2)/M arrest in human cells. Mol Cell Biol 2000; 20: 2358-2366
79. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000; 97: 13103-13107
80. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003; 63: 230-235
81. Konishi Y, Lehtinen M, Donovan N, Bonni A. Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell 2002; 9: 1005-1016
82. Finzer P, Aguilar-Lemarroy A, Rosl F. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett 2002; 188: 15-24
83. Iglesias M, Yen K, Gaiotti D, Hildesheim A, Stoler MH, Woodworth CD. Human papillomavirus type 16 E7 protein sensitizes cervical keratinocytes to apoptosis and release of interleukin-1alpha. Oncogene 1998; 17: 1195-1205
84. Stoppler H, Stoppler MC, Johnson E, Simbulan-Rosenthal CM, Smulson ME, Iyer S, Rosenthal DS, Schlegel R. The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes to apoptosis. Oncogene 1998; 17: 1207-1214
85. Liu Y, McKalip A, Herman B. Human papillomavirus type 16 E6 and HPV-16 E6/E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents: Roles of p53 and caspase activation. J Cell Biochem 2000; 78: 334-349
86. Alfandari J, Shnitman Magal S, Jackman A, Schlegel R, Gonen P, Sherman L. HPV16 E6 oncoprotein inhibits apoptosis induced during serum-calcium differentiation of foreskin human keratinocytes. Virology 1999; 257: 383-396
87. Sherman L, Itzhaki H, Jackman A, Chen JJ, Koval D, Schlegel R. Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16 E6: Study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP. Virology 2002; 292: 309-320
88. Aguilar-Lemarroy A, Gariglio P, Whitaker NJ, Eichhorst ST, zur Hausen H, Krammer PH, Rosl F. Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis. Oncogene 2002; 21: 165-175
89. Magal SS, Jackman A, Pei XF, Schlegel R, Sherman L. Induction of apoptosis in human keratinocytes containing mutated p53 alleles and its inhibition by both the E6 and E7 oncoproteins. Int J Cancer 1998; 75: 96-104
90. Mythily DV, Krishna S, Tergaonkar V. Pleiotropic effects of human papillomavirus type 16 E6 oncogene expression in human epithelial cell lines. J Gen Virol 1999; 80(Pt 7): 1707-1713
91. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 2003; 77: 1551-1563
92. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler E. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 2000; 97: 6693-6697
93. Brown J, Higo H, McKalip A, Herman B. Human papillomavirus (HPV) 16 E6 sensitizes cells to atractyloside-induced apoptosis: Role of p53, ICE-like proteases and the mitochondrial permeability transition. J Cell Biochem 1997; 66: 245-255
94. Pan H, Griep AE. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: Implications for tumor suppressor gene function in development. Genes Dev 1994; 8: 1285-1299
95. Pan H, Griep AE. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev 1995; 9: 2157-2169
96. Steller MA, Zou Z, Schiller JT, Baserga R. Transformation by human papillomavirus 16 E6 and E7: Role of the insulin-like growth factor 1 receptor. Cancer Res 1996; 56: 5087-5091
97. Havre PA, O'Reilly S, McCormick JJ, Brash DE. Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants, N-acetyl cysteine and penicillamine. Cancer Res 2002; 62: 1443-1449
98. Thomas M, Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998; 17: 2943-2954
99. Duerksen Hughes PJ, Yang J, Schwartz SB. HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblast LM cells. Virology 1999; 264: 55-65
100. Vikhanskaya F, Falugi C, Valente P, Russo P. Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. Int J Cancer 2002; 97: 732-739
101. Rapp L, Liu Y, Hong Y, Androphy EJ, Chen JJ. The bovine papillomavirus type 1 E6 oncoprotein sensitizes cells to tumor necrosis factor alpha-induced apoptosis. Oncogene 1999; 18: 607-615
102. Liu Z, Liu Y, Hong Y, Rapp L, Androphy EJ, Chen JJ. Bovine papillomavirus type 1 E6-induced sensitization to apoptosis is distinct from its transforming activity. Virology 2002; 295: 230-237
103. Liu Y, Tergaonkar V, Krishna S, Androphy EJ. Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor alpha correlates with increased accumulation of reactive oxygen species. J Biol Chem 1999; 274: 24819-24827
104. Chen X, Shen B, Xia L, Khaletzkiy A, Chu D, Wong JY, Li JJ. Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res 2002; 62: 1213-1221
105. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat Med 1996; 2: 72-79
106. Passalaris TM, Benanti JA, Gewin L, Kiyono T, Galloway DA. The G(2) checkpoint is maintained by redundant pathways. Mol Cell Biol 1999; 19: 5872-5881
107. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996; 56: 892-898